HK2 Cancer Research Results

HK2, Hexokinase 2: Click to Expand ⟱
Source:
Type: enzyme
HK2 (Hexokinase 2) is an enzyme that plays a crucial role in glycolysis, the process by which cells convert glucose into energy. HK2 is a key regulatory enzyme in the glycolytic pathway, and it is primarily expressed in various tissues, including muscle, brain, and cancer cells.
HK2 has been shown to be overexpressed in many types of tumors, including breast, lung, and colon cancer. This overexpression may contribute to the development and progression of cancer by promoting glycolysis and energy production in cancer cells.
HK2 is a key regulatory enzyme in the glycolytic pathway.
HK2 plays a role in the regulation of glucose metabolism in diabetes.
HK2 is involved in the regulation of cell proliferation, apoptosis, and autophagy.

HK2 Inhibitors:
-2DG
-Curcumin
-Resveratrol
-EGCG
-Berberine
-Methyl Jasmonate (MJ)
-Honokiol
Scientific Papers found: Click to Expand⟱
1576- Citrate,    Targeting citrate as a novel therapeutic strategy in cancer treatment
- Review, Var, NA
TCA↓, T-Cell↝, Glycolysis↓, PKM2↓, PFK2?, SDH↓, PDH↓, β-oxidation↓, CPT1A↓, FASN↑, Casp3↑, Casp2↑, Casp8↑, Casp9↑, cl‑PARP↑, Hif1a↓, GLUT1↓, angioG↓, Ca+2↓, ROS↓, eff↓, Dose↓, eff↑, Mcl-1↓, HK2↓, IGF-1R↓, PTEN↑, citrate↓, Dose∅, eff↑, eff↑, eff↑, eff↑,
990- CUR,    Curcumin inhibits aerobic glycolysis and induces mitochondrial-mediated apoptosis through hexokinase II in human colorectal cancer cells in vitro
- in-vitro, CRC, HCT116 - in-vitro, CRC, HT-29
HK2↓, Glycolysis↓, Apoptosis↑,
2308- CUR,    Counteracting Action of Curcumin on High Glucose-Induced Chemoresistance in Hepatic Carcinoma Cells
- in-vitro, Liver, HepG2
GlucoseCon↓, lactateProd↓, ECAR↓, NO↓, ROS↑, HK2↓, PFK1↓, GAPDH↓, PKM2↓, LDHA↓, FASN↓, GLUT1↓, MCT1↓, MCT4↓, HCAR1↓, SDH↑, ChemoSen↑, ROS↑, BioAv↑, P53↑, NF-kB↓, pH↑,
1861- dietFMD,  Chemo,    Fasting induces anti-Warburg effect that increases respiration but reduces ATP-synthesis to promote apoptosis in colon cancer models
- in-vitro, Colon, CT26 - in-vivo, NA, NA
selectivity↑, ChemoSen↑, BG↓, AminoA↓, Warburg↓, OCR↑, ATP↓, ROS↑, Apoptosis↑, GlucoseCon↓, PI3K↓, PTEN↑, GLUT1↓, GLUT2↓, HK2↓, PFK1↓, PKA↓, ATP:AMP↓, Glycolysis↓, lactateProd↓,
2272- dietMet,    Methionine restriction - Association with redox homeostasis and implications on aging and diseases
- Review, Nor, NA
*OS↑, *mt-ROS↓, *H2S↑, *FGF21↑, *cognitive↑, *GutMicro↑, *IGF-1↓, *mTOR↓, *GSH↑, *SOD↑, *MDA↓, *NRF2↑, *HO-1↑, *NQO1↑, *GLUT4↑, *Glycolysis↑, *HK2↑, *PFK↑, *PKM2↑, *GlucoseCon↑, *ATF4↑, *PPARα↑, GSH↓, GSTs↑, ROS↑, *neuroP↑,
649- EGCG,  CUR,  PI,    Targeting Cancer Hallmarks with Epigallocatechin Gallate (EGCG): Mechanistic Basis and Therapeutic Targets
- Review, Var, NA
*BioEnh↑, EGFR↓, HER2/EBBR2↓, IGF-1↓, MAPK↓, ERK↓, RAS↓, Raf↓, NF-kB↓, p‑pRB↓, TumCCA↑, Glycolysis↓, Warburg↓, HK2↓, Pyruv↓,
681- EGCG,    Suppressing glucose metabolism with epigallocatechin-3-gallate (EGCG) reduces breast cancer cell growth in preclinical models
- vitro+vivo, BC, NA
Casp3↑, Casp8↑, Casp9↑, TumAuto↑, Beclin-1↝, ATG5↝, GlucoseCon↓, lactateProd↓, ATP↝, HK2↓, LDHA↓, Hif1a↓, GLUT1↓, TumVol↓, VEGF↓,
2309- EGCG,  Chemo,    Targeting Glycolysis with Epigallocatechin-3-Gallate Enhances the Efficacy of Chemotherapeutics in Pancreatic Cancer Cells and Xenografts
- in-vitro, PC, MIA PaCa-2 - in-vitro, Nor, HPNE - in-vitro, PC, PANC1 - in-vivo, NA, NA
TumCG↓, eff↑, ROS↑, ECAR↓, ChemoSen↑, selectivity↑, Glycolysis↓, PFK↓, PKA↓, HK2∅, LDHA∅, PFKP↓, PKM2↓, H2O2↑, TumW↓,
2993- EGCG,    Tea polyphenols down-regulate the expression of the androgen receptor in LNCaP prostate cancer cells
- in-vitro, Pca, LNCaP
TumCG↓, PSA↓, HK2↓, AR↓, Sp1/3/4↓,
2458- EGCG,  QC,    Identification of plant-based hexokinase 2 inhibitors: combined molecular docking and dynamics simulation studies
- Analysis, Nor, NA
HK2↓,
2459- EGCG,    Epigallocatechin gallate inhibits human tongue carcinoma cells via HK2‑mediated glycolysis
- in-vitro, Tong, Tca8113 - in-vitro, Tong, TSCCa
EGFR↓, Akt↓, ERK↓, HK2↓, GlucoseCon↓, lactateProd↓, Glycolysis↓,
2460- EGCG,  Taur,    Anti-fibrosis activity of combination therapy with epigallocatechin gallate, taurine and genistein by regulating glycolysis, gluconeogenesis, and ribosomal and lysosomal signaling pathways in HSC-T6 cells
- in-vitro, Nor, HSC-T6
HK2↓,
2422- EMD,    Anti-Cancer Effects of Emodin on HepG2 Cells as Revealed by 1H NMR Based Metabolic Profiling
- in-vitro, HCC, HepG2
HK2↓, PKM2↓, LDHA↓, Glycolysis↓, TumCCA↑, ROS↓, glut↓, Hif1a↓,
2313- Flav,    Flavonoids against the Warburg phenotype—concepts of predictive, preventive and personalised medicine to cut the Gordian knot of cancer cell metabolism
- Review, Var, NA
Warburg↓, antiOx↑, angioG↓, Glycolysis↓, PKM2↓, PKM2:PKM1↓, β-catenin/ZEB1↓, cMyc↓, HK2↓, Akt↓, mTOR↓, GLUT1↓, Hif1a↓,
845- Gra,    A Review on Annona muricata and Its Anticancer Activity
- Review, NA, NA
GlucoseCon↓, ATP↓, HIF-1↓, GLUT1↓, GLUT4↓, HK2↓, LDHA↓, ERK↓, Akt↓, Apoptosis↑, NF-kB↓, ROS↑, Bax:Bcl2↑, MMP↓, Casp3↑, Casp9↑, p‑JNK↓,
836- Gra,    Graviola: A Novel Promising Natural-Derived Drug That Inhibits Tumorigenicity and Metastasis of Pancreatic Cancer Cells In Vitro and In Vivo Through Altering Cell Metabolism
- vitro+vivo, PC, NA
Hif1a↓, NF-kB↓, GLUT1↓, GLUT4↓, HK2↓, LDHA↓, TumCCA↑, TumMeta↓, GlucoseCon↓, ATP↓, necrosis↑, Casp∅, p‑FAK↓, MMP9↓, MUC4↓,
1232- Gra,    Graviola: A Systematic Review on Its Anticancer Properties
- Review, NA, NA
EGFR↓, cycD1/CCND1↓, Bcl-2↓, TumCCA↑, Apoptosis↑, ROS↑, MMP↓, BAX↑, Cyt‑c↑, Hif1a↓, NF-kB↓, GLUT1↓, GLUT4↓, HK2↓, LDHA↓, ATP↓,
2438- Gra,    Emerging therapeutic potential of graviola and its constituents in cancers
- Review, Var, NA
Hif1a↓, GLUT1↓, GLUT4↓, HK2↓, LDHA↓, MUC4↓, TumCCA↑, MMP↓, NF-kB↓, ROS↓, Bax:Bcl2↑, ER(estro)↓, cycD1/CCND1↓, chemoPv↑, hepatoP↑,
2512- H2,    Hydrogen Attenuates Allergic Inflammation by Reversing Energy Metabolic Pathway Switch
- in-vivo, asthmatic, NA
selectivity↑, lactateProd↓, ATP↑, HK2↓, PFK↓, Hif1a↓, PGC-1α↑, Glycolysis↓, OXPHOS↑, Dose↝,
960- HNK,    Honokiol Inhibits HIF-1α-Mediated Glycolysis to Halt Breast Cancer Growth
- vitro+vivo, BC, MCF-7 - vitro+vivo, BC, MDA-MB-231
OCR↑, ECAR↓, GlucoseCon↓, lactateProd↓, ATP↓, Glycolysis↓, Hif1a↓, GLUT1↓, HK2↓, PDK1↓, Apoptosis↑, LDHA↓,
1070- IVM,    Ivermectin accelerates autophagic death of glioma cells by inhibiting glycolysis through blocking GLUT4 mediated JAK/STAT signaling pathway activation
- vitro+vivo, GBM, NA
TumCG↓, LC3II↑, p62↓, ATP↓, Pyruv↓, GlucoseCon↑, HK2↓, PFK1↓, GLUT4↓, Glycolysis↓, JAK2↓, p‑STAT3↓, p‑STAT5↓,
2351- lamb,    Anti-Warburg effect via generation of ROS and inhibition of PKM2/β-catenin mediates apoptosis of lambertianic acid in prostate cancer cells
- in-vitro, Pca, DU145 - in-vitro, Pca, PC3
proCasp3↓, proPARP↓, LDHA↓, Glycolysis↓, HK2↓, PKM2↓, lactateProd↓, p‑STAT3↓, cycD1/CCND1↓, cMyc↓, β-catenin/ZEB1↓, p‑GSK‐3β↓, ROS↑, eff↓,
2453- LE,    The Promoting Role of HK II in Tumor Development and the Research Progress of Its Inhibitors
- Review, Var, NA
HK2↓, PI3K↓, Akt↓, TumCP↓, Glycolysis↓,
2929- LT,    Loss of BRCA1 in the cells of origin of ovarian cancer induces glycolysis: A window of opportunity for ovarian cancer chemoprevention
- in-vitro, Ovarian, NA
HK2↓, Myc↓, Glycolysis↓,
2450- Matr,    The Promoting Role of HK II in Tumor Development and the Research Progress of Its Inhibitors
- Review, Var, NA
HK2↓, eff↓,
994- MET,    Tumor metabolism destruction via metformin-based glycolysis inhibition and glucose oxidase-mediated glucose deprivation for enhanced cancer therapy
- in-vitro, Var, NA
Glycolysis↓, HK2↓, ATP↓, AMPK↑, P53↑, Warburg↓, Apoptosis↑,
2456- MET,    Direct inhibition of hexokinase activity by metformin at least partially impairs glucose metabolism and tumor growth in experimental breast cancer
- in-vitro, BC, MDA-MB-231 - in-vivo, NA, NA
GlucoseCon↓, TumCG↓, HK2↓, p‑AMPK↑, TXNIP↓, *toxicity↓,
2457- MET,    Metformin Impairs Glucose Consumption and Survival in Calu-1 Cells by Direct Inhibition of Hexokinase-II
- in-vitro, Lung, Calu-1
HK1↓, HK2↓, GlucoseCon↓, MMP↓, ATP↓,
2436- MET,    Metformin alleviates nickel-induced autophagy and apoptosis via inhibition of hexokinase-2, activating lipocalin-2, in human bronchial epithelial cells
- in-vitro, Nor, BEAS-2B
*HK2↓,
2385- MET,    Metformin activates chaperone-mediated autophagy and improves disease pathologies in an Alzheimer disease mouse model
- in-vitro, AD, H4 - in-vitro, NA, HEK293 - in-vivo, NA, NA - in-vitro, NA, SH-SY5Y
*HK2↓, *PKM2↓, *Dose↝, IKKα↑, memory↑, p‑Hsc70↑, APP↓,
2249- MF,    Pulsed electromagnetic fields modulate energy metabolism during wound healing process: an in vitro model study
- in-vitro, Nor, L929
*TumCMig↑, *tumCV↑, *Glycolysis↑, *ROS↓, *mitResp↓, *other↝, *OXPHOS↓, *pH↑, *antiOx↑, *PFKM↑, *PFKL↑, *PKM2↑, *HK2↑, *GLUT1↑, *GPx1↑, *GPx4↑, *SOD1↑,
525- MF,    Pulsed electromagnetic fields regulate metabolic reprogramming and mitochondrial fission in endothelial cells for angiogenesis
- in-vitro, Nor, HUVECs
*angioG↑, *GPx1↑, *GPx4↑, *SOD↑, *PFKM↑, *PFKL↑, *PKM2↑, *PFKP↑, *HK2↑, *GLUT1↑, *GLUT4↑, *ROS↓, *MMP↝, *Glycolysis↑, *OXPHOS↓,
991- OA,    Blockade of glycolysis-dependent contraction by oroxylin a via inhibition of lactate dehydrogenase-a in hepatic stellate cells
- in-vivo, NA, NA - in-vivo, Nor, NA
*Glycolysis↓, *GlucoseCon↓, *lactateProd↓, *ECAR↓, *HK2↓, *PFK↓, *PKM2↓, *LDHA↓,
2451- PA,    The Promoting Role of HK II in Tumor Development and the Research Progress of Its Inhibitors
- Review, Var, NA
HK2↓, ATP↓, ROS↑,
2452- PA,    Targeting Pyruvate Kinase M2 and Hexokinase II, Pachymic Acid Impairs Glucose Metabolism and Induces Mitochondrial Apoptosis
- in-vitro, BC, SkBr3
HK2↓, GlucoseCon↓, lactateProd↓, mtDam↑, ATP↓, ROS↑, PKM2↑,
2396- PACs,    PKM2 is the target of proanthocyanidin B2 during the inhibition of hepatocellular carcinoma
- in-vitro, HCC, HCCLM3 - in-vitro, HCC, SMMC-7721 cell - in-vitro, HCC, Bel-7402 - in-vitro, HCC, HUH7 - in-vitro, HCC, HepG2 - in-vitro, Nor, L02
TumCP↓, TumCCA↓, Apoptosis↑, GlucoseCon↓, lactateProd↓, PKM2↓, Glycolysis↓, HK2↓, PFK↓, OXPHOS↑, ChemoSen↑, HSP90↓, Hif1a↓,
2421- PB,    Sodium butyrate inhibits aerobic glycolysis of hepatocellular carcinoma cells via the c‐myc/hexokinase 2 pathway
- in-vitro, HCC, HCCLM3 - in-vivo, NA, NA - in-vitro, HCC, Bel-7402 - in-vitro, HCC, SMMC-7721 cell - in-vitro, Nor, L02
Glycolysis↓, Apoptosis↑, TumCP↓, lactateProd↓, GlucoseCon↓, HK2↓, ChemoSen↑, *toxicity↓, cMyc↓, PFK1↓, LDHA↓, cMyc↓, ChemoSen↑,
1231- PBG,    Caffeic acid phenethyl ester inhibits MDA-MB-231 cell proliferation in inflammatory microenvironment by suppressing glycolysis and lipid metabolism
- in-vitro, BC, MDA-MB-231
TumCP↓, TumCMig↓, TumCI↓, MMP↓, TLR4↓, TNF-α↓, NF-kB↓, IL1β↓, IL6↓, IRAK4↓, GLUT1↓, GLUT3↓, HK2↓, PFK↓, PKM2↓, LDHA↓, ACC↓, FASN↓, eff↓,
1672- PBG,    The Potential Use of Propolis as an Adjunctive Therapy in Breast Cancers
- Review, BC, NA
ChemoSen↓, RadioS↑, Inflam↓, AntiCan↑, Dose∅, mtDam↑, Apoptosis?, OCR↓, ATP↓, ROS↑, ROS↑, LDH↓, TP53↓, Casp3↓, BAX↓, P21↓, ROS↑, eNOS↑, iNOS↑, eff↑, hTERT/TERT↓, cycD1/CCND1↓, eff↑, eff↑, eff↑, eff↑, STAT3↓, TIMP1↓, IL4↓, IL10↓, OS↑, Dose∅, ER Stress↑, ROS↑, NF-kB↓, p65↓, MMP↓, TumAuto↑, LC3II↑, p62↓, TLR4↓, mtDam↑, LDH↓, ROS↑, Glycolysis↓, HK2↓, PFK↓, PKM2↓, LDH↓, IL10↓, HDAC8↓, eff↑, eff↑, P21↑,
1661- PBG,    Propolis: a natural compound with potential as an adjuvant in cancer therapy - a review of signaling pathways
- Review, Var, NA
JNK↓, ERK↓, Akt↓, NF-kB↓, FAK↓, MAPK↓, PI3K↓, Akt↓, P21↑, p27↑, TRAIL↑, BAX↑, P53↑, ERK↓, ChemoSen↑, RadioS↑, Glycolysis↓, HK2↓, PKM2↓, LDHA↓, PFK↓,
1664- PBG,    Anticancer Activity of Propolis and Its Compounds
- Review, Var, NA
Apoptosis↑, TumCMig↓, TumCCA↑, TumCP↓, angioG↓, P21↑, p27↑, CDK1↓, p‑CDK1↓, cycA1/CCNA1↓, CycB/CCNB1↓, P70S6K↓, CLDN2↓, HK2↓, PFK↓, PKM2↓, LDHA↓, TLR4↓, H3↓, α-tubulin↓, ROS↑, Akt↓, GSK‐3β↓, FOXO3↓, NF-kB↓, cycD1/CCND1↓, MMP↓, ROS↑, i-Ca+2↑, lipid-P↑, ER Stress↑, UPR↑, PERK↑, eIF2α↑, GRP78/BiP↑, BAX↑, PUMA↑, ROS↑, MMP↓, Cyt‑c↑, cl‑Casp8↑, cl‑Casp8↑, cl‑Casp3↑, cl‑PARP↑, eff↑, eff↑, RadioS↑, ChemoSen↑, eff↑,
1666- PBG,    Molecular and Cellular Mechanisms of Propolis and Its Polyphenolic Compounds against Cancer
- Review, Var, NA
ChemoSen↑, TumCCA↑, TumCP↓, Apoptosis↑, antiOx↓, ROS↑, COX2↑, ER(estro)↓, cycA1/CCNA1↓, CycB/CCNB1↓, CDK2↓, P21↑, p27↑, hTERT/TERT↓, HDAC↓, ROS⇅, Dose?, ROS↓, ROS↑, DNAdam↑, ChemoSen↑, LOX1↓, lipid-P↓, NO↑, Igs↑, NK cell↑, MMPs↓, VEGF↓, Hif1a↓, GLUT1↓, HK2↓, selectivity↑, RadioS↑, GlucoseCon↓, lactateProd↓, eff↓, *BioAv↓,
2382- PBG,    Integration with Transcriptomic and Metabolomic Analyses Reveals the In Vitro Cytotoxic Mechanisms of Chinese Poplar Propolis by Triggering the Glucose Metabolism in Human Hepatocellular Carcinoma Cells
- in-vitro, HCC, HepG2
TumCP↓, Glycolysis↓, GlucoseCon↓, lactateProd↓, GLUT1↓, GLUT2↓, LDHA↓, HK2↓, PKM2↓, PFK↓, Dose↝,
2381- PBG,    Chinese Poplar Propolis Inhibits MDA-MB-231 Cell Proliferation in an Inflammatory Microenvironment by Targeting Enzymes of the Glycolytic Pathway
- in-vitro, BC, MDA-MB-231
TumCP↓, TumCMig↓, TumCI↓, angioG↓, TNF-α↓, IL1β↓, IL6↓, NLRP3↓, Glycolysis↓, HK2↓, PFK↓, PKM2↓, LDHA↓, ROS↑, MMP↓,
2380- PBG,    Potential Strategies for Overcoming Drug Resistance Pathways Using Propolis and Its Polyphenolic/Flavonoid Compounds in Combination with Chemotherapy and Radiotherapy
- Review, Var, NA
Hif1a↓, Glycolysis↓, PKM2↓, LDHA↓, GLUT2↓, HK2↓, PFK1↓, PDK1↓, chemoP↓, radioP↑,
2946- PL,    Piperlongumine, a potent anticancer phytotherapeutic: Perspectives on contemporary status and future possibilities as an anticancer agent
- Review, Var, NA
ROS↑, GSH↓, DNAdam↑, ChemoSen↑, RadioS↑, BioEnh↑, selectivity↑, BioAv↓, eff↑, p‑Akt↓, mTOR↓, GSK‐3β↓, β-catenin/ZEB1↓, HK2↓, Glycolysis↓, Cyt‑c↑, Casp9↑, Casp3↑, Casp7↑, cl‑PARP↑, TrxR↓, ER Stress↑, ATF4↝, CHOP↑, Prx4↑, NF-kB↓, cycD1/CCND1↓, CDK4↓, CDK6↓, p‑RB1↓, RAS↓, cMyc↓, TumCCA↑, selectivity↑, STAT3↓, NRF2↑, HO-1↑, PTEN↑, P-gp↓, MDR1↓, MRP1↓, survivin↓, Twist↓, AP-1↓, Sp1/3/4↓, STAT1↓, STAT6↓, SOX4↑, XBP-1↑, P21↑, eff↑, Inflam↓, COX2↓, IL6↓, MMP9↓, TumMeta↓, TumCI↓, ICAM-1↓, CXCR4↓, VEGF↓, angioG↓, Half-Life↝, BioAv↑,
2948- PL,    The promising potential of piperlongumine as an emerging therapeutics for cancer
- Review, Var, NA
tumCV↓, TumCP↓, TumCI↓, angioG↓, EMT↓, TumMeta↓, *hepatoP↑, *lipid-P↓, *GSH↑, cardioP↑, CycB/CCNB1↓, cycD1/CCND1↓, CDK2↓, CDK1↓, CDK4↓, CDK6↓, PCNA↓, Akt↓, mTOR↓, Glycolysis↓, NF-kB↓, IKKα↓, JAK1↓, JAK2↓, STAT3↓, ERK↓, cFos↓, Slug↓, E-cadherin↑, TOP2↓, P53↑, P21↑, Bcl-2↓, BAX↑, Casp3↑, Casp7↑, Casp8↑, p‑HER2/EBBR2↓, HO-1↑, NRF2↑, BIM↑, p‑FOXO3↓, Sp1/3/4↓, cMyc↓, EGFR↓, survivin↓, cMET↓, NQO1↑, SOD2↑, TrxR↓, MDM2↓, p‑eIF2α↑, ATF4↑, CHOP↑, MDA↑, Ki-67↓, MMP9↓, Twist↓, SOX2↓, Nanog↓, OCT4↓, N-cadherin↓, Vim↓, Snail↓, TumW↓, TumCG↓, HK2↓, RB1↓, IL6↓, IL8↓, SOD1↑, RadioS↑, ChemoSen↑, toxicity↓, Sp1/3/4↓, GSH↓, SOD↑,
2300- QC,    Flavonoids Targeting HIF-1: Implications on Cancer Metabolism
- Review, Var, NA
AntiTum↑, Hif1a↓, *Hif1a↑, Glycolysis↓, HK2↓, PDK3↓, PFKP?,
2340- QC,    Oral Squamous Cell Carcinoma Cells with Acquired Resistance to Erlotinib Are Sensitive to Anti-Cancer Effect of Quercetin via Pyruvate Kinase M2 (PKM2)
- in-vitro, OS, NA
TumCG↓, GlucoseCon↓, TumCI↓, GLUT1↓, PKM2↓, LDHA↓, Glycolysis↓, lactateProd↓, HK2↓, eff↑,
2342- QC,    Quercetin Inhibits the Proliferation of Glycolysis-Addicted HCC Cells by Reducing Hexokinase 2 and Akt-mTOR Pathway
- in-vitro, HCC, Bel-7402 - in-vitro, HCC, SMMC-7721 cell - in-vivo, NA, NA
TumCP↓, HK2↓, Akt↓, mTOR↓, GlucoseCon↓, lactateProd↓, Glycolysis↓,

Showing Research Papers: 51 to 100 of 140
Prev Page 2 of 3 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 140

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

antiOx↓, 1,   antiOx↑, 1,   GSH↓, 3,   GSTs↑, 1,   H2O2↑, 1,   HK1↓, 1,   HO-1↑, 2,   lipid-P↓, 1,   lipid-P↑, 1,   MDA↑, 1,   NQO1↑, 1,   NRF2↑, 2,   OXPHOS↑, 2,   Prx4↑, 1,   ROS↓, 4,   ROS↑, 22,   ROS⇅, 1,   SOD↑, 1,   SOD1↑, 1,   SOD2↑, 1,   TrxR↓, 2,  

Mitochondria & Bioenergetics ⓘ

ATP↓, 11,   ATP↑, 1,   ATP↝, 1,   MMP↓, 9,   mtDam↑, 3,   OCR↓, 1,   OCR↑, 2,   PGC-1α↑, 1,   Raf↓, 1,   SDH↓, 1,   SDH↑, 1,  

Core Metabolism/Glycolysis ⓘ

ACC↓, 1,   AminoA↓, 1,   AMPK↑, 1,   p‑AMPK↑, 1,   ATP:AMP↓, 1,   citrate↓, 1,   cMyc↓, 6,   CPT1A↓, 1,   ECAR↓, 3,   FASN↓, 2,   FASN↑, 1,   GAPDH↓, 1,   GlucoseCon↓, 16,   GlucoseCon↑, 1,   glut↓, 1,   GLUT2↓, 3,   Glycolysis↓, 27,   HK2↓, 43,   HK2∅, 1,   lactateProd↓, 14,   LDH↓, 3,   LDHA↓, 17,   LDHA∅, 1,   MCT4↓, 1,   PDH↓, 1,   PDK1↓, 2,   PDK3↓, 1,   PFK↓, 9,   PFK1↓, 5,   PFK2?, 1,   PFKP?, 1,   PFKP↓, 1,   PKM2↓, 15,   PKM2↑, 1,   PKM2:PKM1↓, 1,   Pyruv↓, 2,   TCA↓, 1,   Warburg↓, 4,   β-oxidation↓, 1,  

Cell Death ⓘ

Akt↓, 9,   p‑Akt↓, 1,   Apoptosis?, 1,   Apoptosis↑, 10,   BAX↓, 1,   BAX↑, 4,   Bax:Bcl2↑, 2,   Bcl-2↓, 2,   BIM↑, 1,   Casp∅, 1,   Casp2↑, 1,   Casp3↓, 1,   Casp3↑, 5,   cl‑Casp3↑, 1,   proCasp3↓, 1,   Casp7↑, 2,   Casp8↑, 3,   cl‑Casp8↑, 2,   Casp9↑, 4,   Cyt‑c↑, 3,   hTERT/TERT↓, 2,   iNOS↑, 1,   JNK↓, 1,   p‑JNK↓, 1,   MAPK↓, 2,   Mcl-1↓, 1,   MCT1↓, 1,   MDM2↓, 1,   Myc↓, 1,   necrosis↑, 1,   p27↑, 3,   PUMA↑, 1,   survivin↓, 2,   TRAIL↑, 1,  

Kinase & Signal Transduction ⓘ

HER2/EBBR2↓, 1,   p‑HER2/EBBR2↓, 1,   Sp1/3/4↓, 4,  

Transcription & Epigenetics ⓘ

H3↓, 1,   p‑pRB↓, 1,   tumCV↓, 1,  

Protein Folding & ER Stress ⓘ

CHOP↑, 2,   eIF2α↑, 1,   p‑eIF2α↑, 1,   ER Stress↑, 3,   GRP78/BiP↑, 1,   p‑Hsc70↑, 1,   HSP90↓, 1,   PERK↑, 1,   UPR↑, 1,   XBP-1↑, 1,  

Autophagy & Lysosomes ⓘ

ATG5↝, 1,   Beclin-1↝, 1,   LC3II↑, 2,   p62↓, 2,   TumAuto↑, 2,  

DNA Damage & Repair ⓘ

DNAdam↑, 2,   P53↑, 4,   cl‑PARP↑, 3,   proPARP↓, 1,   PCNA↓, 1,   TP53↓, 1,  

Cell Cycle & Senescence ⓘ

CDK1↓, 2,   p‑CDK1↓, 1,   CDK2↓, 2,   CDK4↓, 2,   cycA1/CCNA1↓, 2,   CycB/CCNB1↓, 3,   cycD1/CCND1↓, 7,   P21↓, 1,   P21↑, 6,   RB1↓, 1,   p‑RB1↓, 1,   TumCCA↓, 1,   TumCCA↑, 8,  

Proliferation, Differentiation & Cell State ⓘ

cFos↓, 1,   cMET↓, 1,   EMT↓, 1,   ERK↓, 6,   FOXO3↓, 1,   p‑FOXO3↓, 1,   GSK‐3β↓, 2,   p‑GSK‐3β↓, 1,   HDAC↓, 1,   HDAC8↓, 1,   IGF-1↓, 1,   IGF-1R↓, 1,   mTOR↓, 4,   Nanog↓, 1,   OCT4↓, 1,   P70S6K↓, 1,   PI3K↓, 3,   PTEN↑, 3,   RAS↓, 2,   SOX2↓, 1,   STAT1↓, 1,   STAT3↓, 3,   p‑STAT3↓, 2,   p‑STAT5↓, 1,   STAT6↓, 1,   TOP2↓, 1,   TumCG↓, 6,  

Migration ⓘ

AP-1↓, 1,   APP↓, 1,   Ca+2↓, 1,   i-Ca+2↑, 1,   CLDN2↓, 1,   E-cadherin↑, 1,   FAK↓, 1,   p‑FAK↓, 1,   Ki-67↓, 1,   MMP9↓, 3,   MMPs↓, 1,   MUC4↓, 2,   N-cadherin↓, 1,   PKA↓, 2,   Slug↓, 1,   Snail↓, 1,   SOX4↑, 1,   TIMP1↓, 1,   TumCI↓, 5,   TumCMig↓, 3,   TumCP↓, 10,   TumMeta↓, 3,   Twist↓, 2,   TXNIP↓, 1,   Vim↓, 1,   α-tubulin↓, 1,   β-catenin/ZEB1↓, 3,  

Angiogenesis & Vasculature ⓘ

angioG↓, 6,   ATF4↑, 1,   ATF4↝, 1,   EGFR↓, 4,   eNOS↑, 1,   HIF-1↓, 1,   Hif1a↓, 13,   LOX1↓, 1,   NO↓, 1,   NO↑, 1,   VEGF↓, 3,  

Barriers & Transport ⓘ

GLUT1↓, 14,   GLUT3↓, 1,   GLUT4↓, 5,   P-gp↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   COX2↑, 1,   CXCR4↓, 1,   HCAR1↓, 1,   ICAM-1↓, 1,   Igs↑, 1,   IKKα↓, 1,   IKKα↑, 1,   IL10↓, 2,   IL1β↓, 2,   IL4↓, 1,   IL6↓, 4,   IL8↓, 1,   Inflam↓, 2,   IRAK4↓, 1,   JAK1↓, 1,   JAK2↓, 2,   NF-kB↓, 12,   NK cell↑, 1,   p65↓, 1,   PSA↓, 1,   T-Cell↝, 1,   TLR4↓, 3,   TNF-α↓, 2,  

Cellular Microenvironment ⓘ

pH↑, 1,  

Protein Aggregation ⓘ

NLRP3↓, 1,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 1,   CDK6↓, 2,   ER(estro)↓, 2,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 1,   BioAv↑, 2,   BioEnh↑, 1,   ChemoSen↓, 1,   ChemoSen↑, 12,   Dose?, 1,   Dose↓, 1,   Dose↝, 2,   Dose∅, 3,   eff↓, 5,   eff↑, 19,   Half-Life↝, 1,   MDR1↓, 1,   MRP1↓, 1,   RadioS↑, 6,   selectivity↑, 6,  

Clinical Biomarkers ⓘ

AR↓, 1,   BG↓, 1,   EGFR↓, 4,   HER2/EBBR2↓, 1,   p‑HER2/EBBR2↓, 1,   hTERT/TERT↓, 2,   IL6↓, 4,   Ki-67↓, 1,   LDH↓, 3,   Myc↓, 1,   PSA↓, 1,   TP53↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 1,   AntiTum↑, 1,   cardioP↑, 1,   chemoP↓, 1,   chemoPv↑, 1,   hepatoP↑, 1,   memory↑, 1,   OS↑, 1,   radioP↑, 1,   toxicity↓, 1,   TumVol↓, 1,   TumW↓, 2,  
Total Targets: 283

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 1,   GPx1↑, 2,   GPx4↑, 2,   GSH↑, 2,   HO-1↑, 1,   lipid-P↓, 1,   MDA↓, 1,   NQO1↑, 1,   NRF2↑, 1,   OXPHOS↓, 2,   ROS↓, 2,   mt-ROS↓, 1,   SOD↑, 2,   SOD1↑, 1,  

Mitochondria & Bioenergetics ⓘ

mitResp↓, 1,   MMP↝, 1,  

Core Metabolism/Glycolysis ⓘ

ECAR↓, 1,   FGF21↑, 1,   GlucoseCon↓, 1,   GlucoseCon↑, 1,   Glycolysis↓, 1,   Glycolysis↑, 3,   H2S↑, 1,   HK2↓, 3,   HK2↑, 3,   lactateProd↓, 1,   LDHA↓, 1,   PFK↓, 1,   PFK↑, 1,   PFKL↑, 2,   PFKM↑, 2,   PFKP↑, 1,   PKM2↓, 2,   PKM2↑, 3,   PPARα↑, 1,  

Transcription & Epigenetics ⓘ

other↝, 1,   tumCV↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

IGF-1↓, 1,   mTOR↓, 1,  

Migration ⓘ

TumCMig↑, 1,  

Angiogenesis & Vasculature ⓘ

angioG↑, 1,   ATF4↑, 1,   Hif1a↑, 1,  

Barriers & Transport ⓘ

GLUT1↑, 2,   GLUT4↑, 2,  

Cellular Microenvironment ⓘ

pH↑, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 1,   BioEnh↑, 1,   Dose↝, 1,  

Clinical Biomarkers ⓘ

GutMicro↑, 1,  

Functional Outcomes ⓘ

cognitive↑, 1,   hepatoP↑, 1,   neuroP↑, 1,   OS↑, 1,   toxicity↓, 2,  
Total Targets: 55

Scientific Paper Hit Count for: HK2, Hexokinase 2
14 3-bromopyruvate
8 Quercetin
8 Propolis -bee glue
8 Sulforaphane (mainly Broccoli)
7 2-DeoxyGlucose
7 Baicalein
7 EGCG (Epigallocatechin Gallate)
7 Resveratrol
6 Metformin
5 Chrysin
5 Shikonin
4 Graviola
3 Berberine
3 Capsaicin
3 Citric Acid
3 Curcumin
3 Ursolic acid
2 Apigenin (mainly Parsley)
2 Baicalin
2 Chemotherapy
2 Magnetic Fields
2 Pachymic acid
2 Piperlongumine
2 Silymarin (Milk Thistle) silibinin
2 Vitamin C (Ascorbic Acid)
2 Vitamin D3
1 Sorafenib (brand name Nexavar)
1 Radiotherapy/Radiation
1 cetuximab
1 Alpha-Lipoic-Acid
1 doxorubicin
1 Artemisinin
1 Ashwagandha(Withaferin A)
1 5-fluorouracil
1 Betulinic acid
1 Caffeic acid
1 Chlorogenic acid
1 Cinnamon
1 diet FMD Fasting Mimicking Diet
1 diet Methionine-Restricted Diet
1 Piperine
1 Taurine
1 Emodin
1 flavonoids
1 Hydrogen Gas
1 Honokiol
1 Ivermectin
1 lambertianic acid
1 Licorice
1 Luteolin
1 Matrine
1 Oroxylin-A
1 Proanthocyanidins
1 Phenylbutyrate
1 Rosmarinic acid
1 Thymoquinone
1 triptolide
1 Vitamin K2
1 Wogonin
1 Worenine
1 γ-Tocotrienol
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:773  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page